194 related articles for article (PubMed ID: 33071107)
1. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Urol Oncol; 2021 Apr; 39(4):235.e15-235.e21. PubMed ID: 33071107
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
3. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
4. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
5. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
Briganti A; Gandaglia G; Scuderi S; Gallina A; Colombo R; Fossati N; Barletta F; Pellegrino A; Nocera L; Montorsi F; Necchi A
Eur Urol; 2020 May; 77(5):576-580. PubMed ID: 31911010
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
[TBL] [Abstract][Full Text] [Related]
8. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
[TBL] [Abstract][Full Text] [Related]
9. Pilot Study of [
Eulitt PJ; Altun E; Sheikh A; Wong TZ; Woods ME; Rose TL; Wallen EM; Pruthi RS; Smith AB; Nielsen ME; Whang YE; Kim WY; Godley PA; Basch EM; David GU; Ramirez J; Deal AM; Rathmell WK; Chen RC; Bjurlin MA; Lin W; Lee JK; Milowsky MI
Clin Genitourin Cancer; 2020 Oct; 18(5):378-386.e1. PubMed ID: 32147364
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
[TBL] [Abstract][Full Text] [Related]
11. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
van de Putte EEF; Vegt E; Mertens LS; Bruining A; Hendricksen K; van der Heijden MS; Horenblas S; van Rhijn BWG
Int Urol Nephrol; 2017 Sep; 49(9):1585-1591. PubMed ID: 28674853
[TBL] [Abstract][Full Text] [Related]
14. Utility of Routine Preoperative
Dason S; Wong NC; Donahue TF; Meier A; Zheng J; Mannelli L; Di Paolo PL; Dean LW; McPherson VA; Rosenberg JE; Bajorin DF; Capeanu M; Dalbagni G; Vargas HA; Bochner BH
J Urol; 2020 Aug; 204(2):254-259. PubMed ID: 32134343
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
16. [
Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
[TBL] [Abstract][Full Text] [Related]
18. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
Richters A; van Ginkel N; Meijer RP; Wondergem M; Schoots I; Vis AN; Kiemeney LALM; van Rhijn BWG; Witjes JA; Aben KKH; Mertens LS
BJU Int; 2023 Oct; 132(4):420-427. PubMed ID: 37246479
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
